未登录
分享
收藏
分享
收藏Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
Wang, Wei; Zhang, Shengnan; Dou, Changlin; Hu, Baihui; Song, Hongtao; Qi, Fan; Zhao, Yanyan; Li, Xiaojing; Zhou, Ming; Xie, Jinlian; Deng, Kunhong; Wu, Qian; Ye, Ling; Cui, Chang; Liu, Li; Huang, Jie; Yang, Guoping
分享
收藏
分享
收藏